U.S. markets open in 20 minutes
  • S&P Futures

    4,413.75
    -24.25 (-0.55%)
     
  • Dow Futures

    34,479.00
    -165.00 (-0.48%)
     
  • Nasdaq Futures

    15,189.00
    -114.50 (-0.75%)
     
  • Russell 2000 Futures

    2,239.30
    -15.90 (-0.71%)
     
  • Crude Oil

    73.10
    -0.20 (-0.27%)
     
  • Gold

    1,745.10
    -4.70 (-0.27%)
     
  • Silver

    22.42
    -0.26 (-1.14%)
     
  • EUR/USD

    1.1707
    -0.0040 (-0.34%)
     
  • 10-Yr Bond

    1.4270
    +0.0170 (+1.21%)
     
  • Vix

    20.36
    -0.51 (-2.44%)
     
  • GBP/USD

    1.3661
    -0.0060 (-0.44%)
     
  • USD/JPY

    110.5760
    +0.2750 (+0.25%)
     
  • BTC-USD

    41,066.33
    -2,444.52 (-5.62%)
     
  • CMC Crypto 200

    1,020.72
    -88.20 (-7.95%)
     
  • FTSE 100

    7,048.21
    -30.14 (-0.43%)
     
  • Nikkei 225

    30,248.81
    +609.41 (+2.06%)
     

CytoSorbents Shares Are Trading Higher On Launch Of Trial On Ticagrelor Removal During Cardiothoracic Surgery

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • CytoSorbents Corporation (NASDAQ: CTSO) receives full FDA approval to conduct the STAR-T trial in the U.S. to support regulatory clearance of DrugSorb Antithrombotic Removal (ATR) system for intraoperative ticagrelor removal during cardiothoracic surgery.

  • This study is being performed under the previously announced FDA Breakthrough Designation received in April 2020.

  • STAR-T will enroll up to 120 patients, and enrollment is expected to begin soon.

  • The study's primary endpoint will evaluate whether the use of DrugSorb-ATR with the standard of care reduces the risk of perioperative bleeding complications compared to standard of care alone.

  • The trial will also evaluate reductions in ticagrelor blood levels and additional outcomes to capture the full potential clinical and cost-economic benefits of DrugSorb-ATR.

  • AstraZeneca Plc's (NASDAQ: AZN) Ticagrelor is frequently preferred as first-line therapy in patients with the acute coronary syndrome in preparation for percutaneous coronary intervention (PCI) and stent placement.

  • Price Action: CTSO shares are up 12.5% at $8.27 during the premarket session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.